AstraZeneca Lung Cancer Therapy Combination Shows Promise in Advanced Study
7 Articles
7 Articles
He was able to help patients in the trial live longer without worsening the disease.
A study showed a significant improvement in the time in which patients remain without worsening of the disease. New data from an advanced stage clinical study create prospects for the therapeutic treatment of a specific form of advanced non-small cell lung cancer. AstraZeneca and China's Hutchmed announced that the combination of osimertinib and savoritinib achieved the key goal of a large clinical trial, as it significantly improved progression…
AstraZeneca announces that Tagrisso plus Orpathys demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) in first-line treatment of so-called MET-amplified EGFR-mutated lung cancer.
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
